PLK1 and peripheral neuropathy: Due to poor cancer cell selectivity of microtubule-targeting drugs and their side effects, such as peripheral neuropathy, new anti-mitotic compounds have been actively developed against e.g., mitotic motor proteins Eg5 and Cenp-E [42, 43], Plk1 and Aurora kinases [44–47], and other key facilitators of cell division [48, 49].